Acute Care Syndromic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Target, Sample Type, End User and Country Analysis - Analysis and Forecast, 2023-2033
| 주요 시장 통계 |
| 개시년 |
2023년 |
| 예측년 |
2033년 |
| 개시년 시장 규모 |
34억 3,000만 달러(2023년) |
| 시장 규모 예측 |
34억 3,000만 달러(2023년) |
| CAGR % : |
9.43% |
급성기 신드로믹 검사 시장 규모는 2022년 31억 4,000만 달러에서 예측 기간 중 9.43%의 CAGR로 추이하며, 2033년에는 84억 4,000만 달러 규모로 성장할 것으로 예측됩니다.
신드로믹 검사 패널은 복수의 병원체를 동시에 검출할 수 있는 분자진단 검사입니다. 이 병원체는 일반적으로 임상 증상이 유사하거나 중복되므로 특정 증상에 관해 환자를 보다 적절히 관리하고, 진단을 용이하게 할 수 있습니다.
세계의 급성기 신드로믹 검사 시장은 감염증의 조기 발견에 대한 수요의 증가에 의해 큰 성장을 달성하고 있습니다. 감염증의 유행 증가와 팬데믹 발생의 증가가 시장 성장에서 중요한 역할을 담당하고 있습니다. 또한 지구의 기온 상승이나 세계 각 지역에서의 새로운 감염증 발견도 시장 성장에 영향을 미치고 있습니다.
질환 유형별로는 호흡기질환 부문이 2022년에 56.29%의 점유율을 보이며, 시장을 선도하고 있습니다. 바이러스성 호흡기질환 및 폐렴의 부담은 매우 크므로 신드로믹 진단 검사는 바이러스성 호흡기 병원체와 세균성 호흡기 병원체를 구별하기 위한 우수한 신속한 어프로치이며, 항균제 사용의 최적화를 목표로 하는 병원이나 의사가 시행해야 하는 것입니다.
표적별로는 세균 부문이 2022년에 41.65%의 점유율을 보이며, 시장을 선도하고 있습니다. 세균은 유전 정보를 포함한 제어 중추를 가진 단순한 세포 구조를 가진 미생물이며, DNA는 단일 루프에 포함되어 있습니다. 세균은 동물뿐만이 아니라 인간에게도 감염하는 수많은 종류의 감염증을 일으킬 가능성이 있습니다. 이 감염증은, 피부, 뇌, 폐, 혈액 등 인체의 모든 부위에 영향을 미칠 가능성이 있습니다. 감염증은 세균이 증식하는 것에 따라 증가하며, 감염 범위가 확대합니다.
샘플 유형별로는 스왑 부문이 2022년에 51.90%의 점유율을 보이며, 시장을 선도하고 있습니다. 스왑의 인기가 높아지고 있는 주요 이유는 사용하기 쉽고, 비침습적이며, 저가 샘플링 방법이기 때문입니다.
최종사용자별로는 병원 부문이 2022년에 42.53%의 점유율을 보이며, 시장을 선도하고 있습니다. 병원은 일상적인 의료 시술에 신드로믹 검사 패널을 채택하는데 앞장서고 있습니다. 특히 북미 및 유럽과 아시아태평양의 병원에서 환자에세 우수한 케어를 제공하기 위해 신드로믹 검사 패널 및 어세이를 도입하고 있습니다.
지역별로는 기존 기업이 많으므로 북미가 2022년에 40.41%로 최대 점유율을 나타냈습니다. 또한 승인 취득의 증가와 상승효과도 이 시장에서 우위성을 높이고 있습니다. 한편, 아시아태평양, 특히 중국 및 인도 등 인구가 많은 국가에서도 신드로믹 패널의 채택이 증가하고 있으며, 성장률에서는 아시아태평양이 10.97%의 CAGR로 최대 성장을 보이고 있습니다.
세계의 급성기 신드로믹 검사 시장을 조사했으며, 시장의 정의와 개요, EV 분리·분석 방법, 법규제·상환 환경, 시장 영향요인 및 시장 기회 분석, 시장 규모의 추이·예측, 각종 구분·지역별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 시장
- 제품의 정의
- 포함 기준과 제외 기준
- 시장 범위
- 조사 방법
제2장 시장 개요
- 개요
- 급성기 신드로믹 검사 워크플로우 분석
- 시장 발자국과 성장 가능성
- 향후 잠재성
제3장 산업 인사이트
- 이해관계자의 시점
- 법규제 프레임워크
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 기타 지역
- 제품 벤치마킹
제4장 시장 역학
- 개요
- 영향 분석
- 시장 촉진요인
- 시장이 해결해야 할 과제
- 시장 기회
제5장 경쟁에 관한 인사이트
- 개요
- 주요 전략·도입
- 시장 점유율 분석
- 성장 점유율 분석
제6장 세계의 급성기 신드로믹 검사 시장 : 질환 유형별
- 개요
- 경쟁 분석
- 호흡기질환
- 소화기 질환
- 비뇨생식기 질환
- 열대병
- 기타
제7장 세계의 급성기 신드로믹 검사 시장 : 표적별
제8장 세계의 급성기 신드로믹 검사 시장 : 샘플 유형별
제9장 세계의 급성기 신드로믹 검사 시장 : 최종사용자별
제10장 세계의 급성기 신드로믹 검사 시장 : 지역별
- 개요
- 북미
- 아시아태평양
- 유럽
- 라틴아메리카
- 기타 지역
제11장 기업 개요
- Acute Care Syndromic Testing Ecosystem Active Players
- Abbott Laboratories
- Becton, Dickinson and Company
- Biocartis NV
- bioMerieux SA(BioFire Diagnostics)
- Danaher Corporation(Cepheid, Inc.)
- DiaSorin S.p.A(Luminex Corporation)
- Eurofins Scientific(Eurofins Viracor)
- Karius
- Laboratory Corporation of America Holdings.
- QIAGEN N.V.
- QuantuMDx Group Ltd.
- Seegene Inc.
- Siemens Healthineers AG
- SpeeDx
- Thermo Fisher Scientific Inc.
KSA
“Global Acute Care Syndromic Testing Market to Reach $8.44 Billion by 2033.”
Introduction of Acute Care Syndromic Testing
The acute care syndromic testing market was valued at $3.14 billion in 2022 and is expected to reach $8.44 billion by 2033, growing at a CAGR of 9.43% between 2023 and 2033. Syndromic panels are molecular diagnostics tests that can detect more than one pathogen at the same time. These pathogens generally have similar or overlapping clinical symptomatology, which enables better management of patients and easier diagnosis with respect to certain symptoms.
| KEY MARKET STATISTICS |
| Start Year | 2023 |
| Forecast Year | 2033 |
| Start Value | $3.43 Billion in 2023 |
| Forecast Value | $3.43 Billion in 2023 |
| CAGR % | 9.43% |
Market Introduction
Before the advent of syndromic tests' physicians relied on the single-plex test, which could detect one pathogen at a time, and multiple tests had to be done to finally identify the pathogen causing the disease. Additionally, till all the tests were completed, physicians had to rely on general therapy until definitive results were available. This delayed the treatment process. As per BIS research, the acute care syndromic testing market includes panels and instruments that can test for more than one type of pathogen and specific instruments that are used to perform these tests. These are predominantly polymerase chain reaction-based testing kits, panels, or assays. The most common syndromic testing panels include respiratory, gastrointestinal, genitourinary, and tropical diseases, among others.
Industrial Impact
The global acute care syndromic testing market has witnessed significant growth, attributed to the increasing demand for early detection of infectious diseases. The increasing prevalence of infectious diseases and the increasing occurrence of pandemics have played a critical role in market growth. Furthermore, the rising temperature of the planet and the detection of new infectious disease in regions around the world is also influencing the market growth.
Global acute care syndromic testing has immense potential to deliver the next level of healthcare solutions. For instance, in April 2023, Abbott Laboratories partnered with the Climate Amplified Disease and Epidemics (CLIMADE) consortium, which is a group of more than 100 scientists globally in various academia and public health agencies. With this partnership, they plan to use diagnostic testing and data science technologies to mitigate future disease outbreaks. Additionally, the advent of better diagnosing, predicting, treating, and monitoring tools for infectious diseases is driving the acute care syndromic testing market growth. Other factors also impact the market growth, including increased patient demand and low turnaround time of these tests.
Market Segmentation:
Segmentation 1: by Disease Type
- Respiratory Diseases
- Upper Respiratory Tract Infections
- Lower Respiratory Tract Infections
- Gastrointestinal Diseases
- Genitourinary Diseases
- Urinary Tract Diseases
- Sexually Transmitted Diseases
- Tropical Diseases
- Other Disease Types
Respiratory Diseases Segment to Dominate the Global Acute Care Syndromic Testing Market (by Disease Type)
The acute care syndromic testing market is led by the respiratory panels, with a 56.29% share in 2022. The burden of viral respiratory illnesses and pneumonia is huge, and thus syndromic diagnostic testing is a good and fast approach to distinguish between viral and bacterial respiratory pathogens and should be implemented by hospitals and doctors aiming to optimize antimicrobial use.
Segmentation 2: by Target
- Bacteria
- Viruses
- Fungi
- Parasites
Bacteria Segment to Dominate the Global Acute Care Syndromic Testing Market (by Target)
The acute care syndromic testing market is led by bacteria panels, with a 41.65% share in 2022. Bacteria are microbes that have a simple cell structure with a control center that contains genetic information, and the DNA is contained in a single loop. Bacterial can cause numerous types of infections that can affect humans as well as animals. These infections can affect the skin, brain, lungs, blood, or any other body part of the human body. The infection increases as the bacteria multiply and that increase the area of infection.
Segmentation 3: by Sample Type
- Blood
- Urine
- Biofluids
- Stool
- Swabs
- Others
Swabs Segment to Dominate the Global Acute Care Syndromic Testing Market (by Sample Type)
The acute care syndromic testing market is led by swabs, with a 51.90% share in 2022. The key reason for the increasing popularity of swabs is that it is an easy-to-use, non-invasive, and inexpensive sampling method.
Segmentation 4: by End User
- Hospitals
- Clinical and Diagnostic Laboratories
- Research and Academic Institutions
- Other End Users
Hospitals Segment to Dominate the Global Acute Care Syndromic Testing Market (by End User)
The acute care syndromic testing market is led by hospitals, with a 42.53% share in 2022. Hospitals are also at the forefront of adopting syndromic testing panels into routine healthcare procedures. Hospitals, particularly in leading regions such as North America and Europe, and also to a certain extent in Asia-Pacific, have incorporated syndromic testing panels and assays to provide superior care to patients.
Segmentation 5: by Region
- North America - U.S., Canada
- Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
- Asia-Pacific - Japan, India, China, South Korea, Australia, and Rest-of-Asia-Pacific
- Latin America - Brazil, Mexico, and Rest-of-Latin America
North America held the highest market share at 40.41% in 2022, mainly due to the high number of legacy companies in the region. Further, increasing approvals and synergistic activities are also increasing their dominance in the market. However, the highest CAGR in the market was seen by Asia-Pacific at 10.97% due to the increasing adoption of syndromic panels in the region, especially in highly populated countries such as China and India.
Recent Developments in the Acute Care Syndromic Testing Market
- In May 2023, Hologic, Inc. got FDA clearance for its Panther Fusion SARS-CoV-2/Flu A/B/RSV assay. This molecular diagnostic test can test for the most prevalent respiratory viruses exhibiting similar conditions all at once, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A (flu A), influenza B (flu B), and respiratory syncytial virus (RSV).
- In March 2023, Lucira Health got FDA approval for its home testing kit that can detect respiratory infections, including COVID-19 and flu. It is easy to use at-home test and can be done on children as young as two years old.
- In April 2023, Abbott Laboratories partnered with the Climate Amplified Disease and Epidemics (CLIMADE) consortium, which is a group of more than 100 scientists globally in various academia and public health agencies. With this partnership, they plan to use diagnostic testing and data science technologies to mitigate future disease outbreaks.
- In May 2023, Applied BioCode, Inc. made an agreement with Medline Industries, which is an industry leader in distributing healthcare products. Medline Industries agreed to distribute the MDx-3000 system, which enables the diagnosis of gastrointestinal and upper respiratory infections, in addition to a suite of Analyte Specific Reagents (ASRs).
- In April 2023, QIAGEN N.V. announced the availability of its QIAstat-Dx syndromic testing solution in Japan, which can detect more than 20 respiratory pathogens, including SARS-CoV-2, from a single sample.
- In January 2023, Fusion Genomics established a fully automated, first-of-its-kind facility for infectious disease surveillance at the Toronto Pearson Internation Airport. This facility is using the company's ONETest platform for the detection of SARS-CoV-2 and other respiratory pathogens in wastewater.
Demand - Drivers, Challenges, and Opportunities
Market Demand Drivers:
- Faster Results Acquired with Syndromic Tests: The traditional single-plex testing methods for infectious disease detection use methods such as microscopy and bacterial culture, whereas syndromic multi-plex tests use PCRs. This is where syndromic testing really shines, as PCR testing is more accurate and less time-consuming. These quick and comprehensive results then allow physicians to provide better care for the patients and make faster clinical decisions.
- Increasing Incidence of Infectious Diseases: The global health system is undergoing severe change as the incidence of infectious diseases constantly increases and building a system against known and unknown pathogen threats. Governments from all over the world have joined hands to maintain the risk of the pandemic at all levels, including the different regional levels such as local, national, and regional. Even though this global health system is doing a lot to protect and promote human health, the world is always being confronted by numerous emerging, reemerging, and longstanding infectious diseases.
- Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing: Diagnosis of infectious diseases can be made much easier with the help of syndromic testing. This benefits not only the individual patient but the institution as a whole in numerous ways, especially by decreasing the costs for patients drastically. If the correct pathogen is not detected on the first try using singleplex testing, then subsequent tests are just an added cost which also takes patients time till the final diagnosis. Higher treatment costs due to later diagnosis and, thus, more aggressive treatment measures are big issues that can be addressed with the use of syndromic panels and decrease the personal and economic burden on the individual and their family/friends.
Market Challenges:
- The Need for Better Reimbursement of Syndromic Tests: Syndromic panels have faster turnaround time and can save patients money in the long run. However, there is still a gap in the reimbursement of these panels. This is because not all syndromic panels are FDA-approved and thus are not reimbursed. Additionally, all home-use panels, including the ones approved by the FDA, are not reimbursed. This slows down the adoption of these syndromic panels, which can only increase to all income classes if either these panels are constantly reimbursed, or the cost of syndromic panels drastically decreases.
- Lack of High-Complexity Testing Center: With the ongoing rapid advancements, new genomic platforms require significant capital investment and high-test volume to enable operation at scale and achieve competitive price points. Additionally, there is also difficulty in establishing and maintaining different technology platforms.
Market Opportunities:
- Quick Access to Treatment and Reduced Use of Antibiotics: When diagnosed with an infectious disease, the most efficient cure for late-stage infections is antibiotics. This can be combated with the use of syndromic testing, as it can help to detect pathogens at the earliest stages. According to a report by Zhu et al. published in 2019, stated that antibiotic prescriptions could be reduced by 30% with the use of syndromic testing.
- High Number of Synergic Activities and Mergers and Acquisitions: The acute care syndromic testing market has witnessed many synergistic activities and mergers and acquisitions since January 2020. This is leading to the consolidation of the market. In June 2022, R-Biopharm acquired AusDiagnostics and with it their wide range of syndromic diseases testing product range.
How Can This Report Add Value to an Organization?
- Product/Innovation Strategy: The global acute care syndromic testing market has been extensively segmented on the basis of various categories, such as disease type, target, sample type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
- Growth/Marketing Strategy: Synergistic activities, product launches, and approvals accounted for the maximum number of key developments, i.e., nearly 91% of the total developments in the global acute care syndromic testing market were between January 2021 to June 2023.
- Competitive Strategy: The global acute care syndromic testing market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the global acute care syndromic testing market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
The top disease-type segment players who are leading capture around 56.30% of the presence in the market. Players in other industries, such as gastrointestinal, genitourinary, and tropical disease, among others, account for approximately 43.70% of the presence in the market.
Key Companies Profiled:
- Abbott Laboratories
- Becton, Dickinson and Company
- Biocartis NV
- bioMerieux SA (BioFire Diagnostics)
- Danaher Corporation (Cepheid, Inc.)
- DiaSorin S.p.A (Luminex Corporation)
- Eurofins Scientific (Eurofins Viracor)
- Karius
|
- Laboratory Corporation of America Holdings.
- QIAGEN N.V.
- QuantuMDx Group Ltd.
- Seegene Inc.
- Siemens Healthineers AG
- SpeeDx
- Thermo Fisher Scientific Inc.
|
Table of Contents
1 Markets
- 1.1 Product Definition
- 1.2 Inclusion and Exclusion Criteria
- 1.3 Market Scope
- 1.3.1 Scope of the Study
- 1.3.2 Key Questions Answered in the Report
- 1.4 Research Methodology
- 1.4.1 Global Acute Care Syndromic Testing Market: Research Methodology
- 1.4.2 Data Sources
- 1.4.2.1 Primary Data Sources
- 1.4.2.2 Secondary Data Sources
- 1.4.3 Market Estimation Model
- 1.4.4 Criteria for Company Profiling
2 Market Overview
- 2.1 Overview
- 2.2 Acute Care Syndromic Testing Workflow Analysis
- 2.3 Market Footprint and Growth Potential
- 2.4 Future Potential
3 Industry Insight
- 3.1 Stakeholder's Perspective (N=20)
- 3.1.1 Physician's Perception
- 3.1.2 Payor's Perception
- 3.1.3 Investor's Perception
- 3.2 Legal and Regulatory Framework of the Global Acute Care Syndromic Testing Market
- 3.2.1 Regulatory Framework in North America
- 3.2.1.1 The U.S.
- 3.2.1.2 Canada
- 3.2.2 Regulatory Framework in Europe
- 3.2.3 Regulatory Framework in Asia-Pacific
- 3.2.3.1 Japan
- 3.2.3.2 China
- 3.2.3.3 India
- 3.2.3.4 South Korea
- 3.2.3.5 Australia
- 3.2.4 Regulatory Framework in Latin America
- 3.2.4.1 Brazil
- 3.2.4.2 Mexico
- 3.2.5 Regulatory Framework in Rest-of-the-World
- 3.2.5.1 U.A.E.
- 3.2.5.2 K.S.A.
- 3.3 Product Benchmarking
4 Market Dynamics
- 4.1 Overview
- 4.2 Impact Analysis
- 4.3 Market Drivers
- 4.3.1 Faster Results Acquired with Syndromic Tests
- 4.3.2 Increasing Incidence of Infectious Diseases
- 4.3.3 Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing
- 4.3.4 Reduced Severe Adverse Effects from Pathogens
- 4.4 Market Challenges
- 4.4.1 Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
- 4.4.2 Lack of High-Complexity Testing Centres
- 4.5 Market Opportunities
- 4.5.1 Quick Access to Treatment and Reduced Use of Antibiotics
- 4.5.2 High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years
5 Competitive Insight
- 5.1 Overview
- 5.2 Key Strategies and Developments
- 5.2.1 Synergistic Activities
- 5.2.2 Product Launches and Product Approvals
- 5.2.3 Funding and Expansion
- 5.2.4 Mergers and Acquisitions
- 5.3 Market Share Analysis (2022)
- 5.4 Growth-Share Analysis (2022)
- 5.4.1 Growth-Share Analysis (by Disease Type)
- 5.4.2 Growth-Share Analysis (by Target)
6 Global Acute Care Syndromic Testing Market (By Disease Type), 2022-2033
- 6.1 Overview
- 6.2 Competitive Analysis
- 6.3 Respiratory Diseases
- 6.3.1 Upper Respiratory Tract Infections
- 6.3.2 Lower Respiratory Tract Infections
- 6.4 Gastrointestinal Diseases
- 6.5 Genitourinary Diseases
- 6.5.1 Urinary Tract Infections
- 6.5.2 Sexually Transmitted Diseases
- 6.6 Tropical Diseases
- 6.7 Others
7 Global Acute Care Syndromic Testing Market (By Target), 2022-2033
- 7.1 Overview
- 7.2 Bacteria
- 7.2.1 Gram-Positive Bacteria
- 7.2.2 Gram-Negative Bacteria
- 7.3 Viruses
- 7.4 Fungi
- 7.5 Parasites
8 Global Acute Care Syndromic Testing Market (By Sample Type), 2022-2033
- 8.1 Overview
- 8.2 Blood
- 8.3 Urine
- 8.4 Biofluids
- 8.4.1 Saliva
- 8.4.2 Sputum
- 8.5 Stool
- 8.6 Swabs
- 8.6.1 Genital Swabs
- 8.6.2 Nasopharyngeal Swabs
- 8.7 Other Sample Types
9 Global Acute Care Syndromic Testing Market (By End User), 2022-2033
- 9.1 Overview
- 9.2 Hospitals
- 9.3 Clinical and Diagnostic Laboratories
- 9.4 Research and Academic Institutions
- 9.5 Other End Users
10 Global Acute Care Syndromic Testing Market (By Region), 2022-2033
- 10.1 Overview
- 10.2 North America
- 10.2.1 North America Acute Care Syndromic Testing Market, By End User
- 10.2.2 North America Acute Care Syndromic Testing Market, By Country
- 10.2.2.1 U.S.
- 10.2.2.2 Canada
- 10.3 Asia-Pacific
- 10.3.1 Asia-Pacific Acute Care Syndromic Testing Market, By End User
- 10.3.2 Asia-Pacific Acute Care Syndromic Testing Market, By Country
- 10.3.2.1 China
- 10.3.2.2 Japan
- 10.3.2.3 India
- 10.3.2.4 Australia
- 10.3.2.5 South Korea
- 10.3.2.6 Rest-of-Asia-Pacific
- 10.4 Europe
- 10.4.1 Europe Acute Care Syndromic Testing Market, By End User
- 10.4.2 Europe Acute Care Syndromic Testing Market, By Country
- 10.4.2.1 Germany
- 10.4.2.2 France
- 10.4.2.3 U.K.
- 10.4.2.4 Italy
- 10.4.2.5 Spain
- 10.4.2.6 Rest-of-Europe
- 10.5 Latin America
- 10.5.1 Latin America Acute Care Syndromic Testing Market, By End User
- 10.5.2 Latin America Acute Care Syndromic Testing Market, By Country
- 10.5.2.1 Brazil
- 10.5.2.2 Mexico
- 10.5.2.3 Rest-of-Latin America
- 10.6 Rest-of-the-World
- 10.6.1 Rest-of-the-World Acute Care Syndromic Testing Market, By End User
11 Company Profiles
- 11.1 Overview
- 11.2 Acute Care Syndromic Testing Ecosystem Active Players
- 11.3 Abbott Laboratories
- 11.3.1 Company Overview
- 11.3.2 Role of Abbott Laboratories in the Global Acute Care Syndromic Testing Market
- 11.3.3 Financials
- 11.3.4 Recent Developments
- 11.3.4.1 Corporate Strategies
- 11.3.4.2 Business Strategies
- 11.3.5 Analyst Perspective
- 11.4 Becton, Dickinson and Company
- 11.4.1 Company Overview
- 11.4.2 Role of Becton, Dickinson and Company in the Global Acute Care Syndromic Testing Market
- 11.4.3 Financials
- 11.4.4 Recent Developments
- 11.4.4.1 Corporate Strategies
- 11.4.4.2 Business Strategies
- 11.4.5 Analyst Perspective
- 11.5 Biocartis NV
- 11.5.1 Company Overview
- 11.5.2 Role of Biocartis NV in the Global Acute Care Syndromic Testing Market
- 11.5.3 Financials
- 11.5.4 Recent Developments
- 11.5.4.1 Business Strategies
- 11.5.5 Analyst Perspective
- 11.6 bioMerieux SA (BioFire Diagnostics)
- 11.6.1 Company Overview
- 11.6.2 Role of bioMerieux SA (BioFire Diagnostics) in the Global Acute Care Syndromic Testing Market
- 11.6.3 Financials
- 11.6.4 Recent Developments
- 11.6.4.1 Business Strategies
- 11.6.5 Analyst Perspective
- 11.7 Danaher Corporation (Cepheid, Inc.)
- 11.7.1 Company Overview
- 11.7.2 Role of Danaher Corporation (Cepheid, Inc.) in the Global Acute Care Syndromic Testing Market
- 11.7.3 Financials
- 11.7.4 Recent Developments
- 11.7.4.1 Corporate Strategies
- 11.7.4.2 Business Strategies
- 11.7.5 Analyst Perspective
- 11.8 DiaSorin S.p.A (Luminex Corporation)
- 11.8.1 Company Overview
- 11.8.2 Role of DiaSorin S.p.A (Luminex Corporation) in the Global Acute Care Syndromic Testing Market
- 11.8.3 Financials
- 11.8.4 Recent Developments
- 11.8.4.1 Corporate Strategies
- 11.8.4.2 Business Strategies
- 11.8.5 Analyst Perspective
- 11.9 Eurofins Scientific (Eurofins Viracor)
- 11.9.1 Company Overview
- 11.9.2 Role of Eurofins Scientific (Eurofins Viracor) in the Global Acute Care Syndromic Testing Market
- 11.9.3 Financials
- 11.9.4 Recent Developments
- 11.9.4.1 Business Strategies
- 11.9.5 Analyst Perspective
- 11.1 Karius
- 11.10.1 Company Overview
- 11.10.2 Role of Karius in the Global Acute Care Syndromic Testing Market
- 11.10.3 Recent Developments
- 11.10.3.1 Business Strategies
- 11.10.4 Analyst Perspective
- 11.11 Laboratory Corporation of America Holdings.
- 11.11.1 Company Overview
- 11.11.2 Role of Laboratory Corporation of America Holdings. in the Global Acute Care Syndromic Testing Market
- 11.11.3 Financials
- 11.11.4 Analyst Perspective
- 11.12 QIAGEN N.V.
- 11.12.1 Company Overview
- 11.12.2 Role of QIAGEN N.V. in the Global Acute Care Syndromic Testing Market
- 11.12.3 Financials
- 11.12.4 Recent Developments
- 11.12.4.1 Business Strategies
- 11.12.5 Analyst Perspective
- 11.13 QuantuMDx Group Ltd.
- 11.13.1 Company Overview
- 11.13.2 Role of QuantuMDx Group Ltd. in the Global Acute Care Syndromic Testing Market
- 11.13.3 Recent Developments
- 11.13.3.1 Corporate Strategies
- 11.13.3.2 Business Strategies
- 11.13.4 Analyst Perspective
- 11.14 Seegene Inc.
- 11.14.1 Company Overview
- 11.14.2 Role of Seegene, Inc. in the Global Acute Care Syndromic Testing Market
- 11.14.3 Financials
- 11.14.4 Recent Developments
- 11.14.4.1 Corporate Strategies
- 11.14.4.2 Business Strategies
- 11.14.5 Analyst Perspective
- 11.15 Siemens Healthineers AG
- 11.15.1 Company Overview
- 11.15.2 Role of Siemens Healthineers AG in the Global Acute Care Syndromic Testing Market
- 11.15.3 Financials
- 11.15.4 Analyst Perspective
- 11.16 SpeeDx
- 11.16.1 Company Overview
- 11.16.2 Role of SpeeDX in the Global Acute Care Syndromic Testing Market
- 11.16.3 Analyst Perspective
- 11.17 Thermo Fisher Scientific Inc.
- 11.17.1 Company Overview
- 11.17.2 Role of Thermo Fisher Scientific Inc. in the Global Acute Care Syndromic Testing Market
- 11.17.3 Financials
- 11.17.4 Recent Developments
- 11.17.4.1 Business Strategies
- 11.17.5 Analyst Perspective
